What factors drove the changes in Tg Therapeutics's revenue and profit?

What is Tg Therapeutics's latest dividend and current dividend yield?

What is the market's earnings forecast for Tg Therapeutics next quarter?

What is the revenue and EPS growth rate for Tg Therapeutics year over year?

What does Tg Therapeutics do and what are its main business segments?

What were the key takeaways from Tg Therapeutics’s earnings call?

What guidance did Tg Therapeutics's management provide for the next earnings period?

Did Tg Therapeutics beat or miss consensus estimates last quarter?

- **Revenue Growth**: 2025 total revenue $616 million, Q4 U.S. sales $183 million (92% YoY growth).
- **BRIUMVI Momentum**: 6-year data shows 90% disability-free patients; subcu trial 75% enrolled for 2026 readout.
- **Financial Strength**: $447 million net income in 2025; $600 million+ balance sheet supports $100M+ buybacks.
- **Strategic Initiatives**: ENHANCE trial for single-dose IV, subcu launch potential 2028, and Azer-cel CAR-T expansion.
- **2026 Outlook**: $825-850 million U.S. BRIUMVI sales guidance; subcu could double addressable market.

**【CEO Summary Section】**
- Total global revenue for 2025: $616 million, with U.S. BRIUMVI net sales at $594 million.
- Q4 2025 U.S. net sales: $183 million (92% YoY growth, 20% sequential growth).
- 6-year BRIUMVI data highlights: 90% of patients free from 24-week confirmed disability progression, 1 relapse per 83 years of treatment.
- ENHANCE trial (single 600mg dose) enrollment complete; top-line data expected mid-2026.
- Subcutaneous BRIUMVI Phase III trial 75% enrolled; potential 2028 launch with quarterly or every-2-month dosing.
- Azer-cel CAR-T trial for progressive MS showing strong patient demand.
- 2026 financial outlook: $825-850 million U.S. BRIUMVI net sales, $875-900 million global revenue.
- Share buybacks: $100 million program completed; additional $100 million authorized.

**【CFO Financial Commentary】**
- Q4 2025 GAAP net income: $23 million ($0.14 per share); full-year 2025 net income: $447.2 million ($2.77 per share).
- 2025 operating expenses: $328 million (in line with $300-320 million guidance).
- 2026 operating expenses: $350 million (excluding non-cash comp) + $100 million for subcu manufacturing.
- Balance sheet: $600 million in current assets, $200 million cash, $300 million A/R, $140 million inventory.

**【Q&A Key Highlights】**
- **Subcu Development**: Phase III trial 75% enrolled; top-line data late 2026/early 2027. Potential to double addressable market if successful.
- **Gross to Net Dynamics**: Q1 2026 headwinds from deductible resets, but full-year guidance unchanged.
- **Patient Starts**: New patient enrollments at record levels; 2026 tracking strongest since launch.
- **Competitive Position**: BRIUMVI gaining share in IV anti-CD20 segment despite new entrants.
- **Subcu Launch Strategy**: U.S. launch focused on existing field force; ex-U.S. strategy to be determined with partner Neuraxpharm.
- **ENHANCE Trial Impact**: Potential to simplify treatment and drive market share gains with single-dose regimen.

TG Therapeutics, Inc.(TGTX)-20260226-2025 Q4 Earnings call transcript

- **Revenue Growth**: Q3 U.S. BRIUMVI sales of $153 million (+93% YoY), full-year guidance raised to $585 million.
- **Pipeline Momentum**: Subcu ublituximab could double CD20 market; ENHANCE study on track for 2027 launch.
- **Financial Strength**: $390 million net income, $178 million cash, and $200 million share buyback program completed/authorized.
- **Strategic Focus**: DTC campaigns driving awareness, subcu product expansion, and disciplined capital allocation.

**【CEO Summary Section】**
- BRIUMVI achieved strong Q3 performance with U.S. net sales of $153 million, driving total revenue growth of 93% YoY and 15% QoQ. 
- Launched two pivotal studies: ENHANCE (simplified dosing schedule) and subcutaneous ublituximab (self-administered option). ENHANCE enrollment completed ahead of schedule, with potential data in mid-2026 and launch in 2027. Subcu ublituximab could expand the CD20 market by nearly doubling the addressable patient population.
- Completed $100 million share repurchase program, with another $100 million authorized, reflecting financial discipline and shareholder return focus.

**【Commercial Update (Adam Waldman)】**
- BRIUMVI U.S. net sales reached $153 million in Q3, exceeding internal and Street expectations. Full-year guidance raised to $585 million (from $575 million), reflecting 14% QoQ growth in Q4.
- Market penetration strengthened with 90% of patients relapse-free after 6 years of treatment, and 0.012 annualized relapse rate. Subcu ublituximab could capture 35-40% of new starts, potentially doubling the CD20 market.
- Direct-to-consumer (DTC) campaigns drove brand awareness and patient engagement, with encouraging early metrics on search volume and website traffic.

**【Financial Highlights (Sean Power)】**
- Q3 GAAP net income of $390.9 million ($2.43 EPS), driven by BRIUMVI revenue growth and a $365 million tax benefit from deferred tax asset release.
- Total revenue $161.7 million (93% YoY growth), with product revenue $159.3 million. Operating expenses $86.6 million, on track for $300-320 million annual guidance.
- Cash balance of $178 million, supporting long-term pipeline investments and strategic flexibility.

**【Q&A Highlights】**
- **Market Dynamics**: Subcu segment accounts for ~35-40% of new starts, with BRIUMVI maintaining leadership in IV market. DTC campaigns expected to accelerate new patient growth in 2026.
- **Pipeline Progress**: Subcu ublituximab pivotal data anticipated in late 2026/early 2027, with potential launch in 2028. ENHANCE simplified dosing regimen could enhance patient convenience and adherence.
- **Financial Strategy**: No immediate M&A plans, prioritizing organic growth and shareholder returns. 2026 guidance to be provided in Q1 2026, with focus on BRIUMVI persistence rates and pipeline milestones.

TG Therapeutics, Inc. (TGTX) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 sales up 91% YoY to $139M, full-year guidance raised to $575M. 
- **Subcu Expansion**: 2028 launch target for self-administered BRIUMVI, targeting 35-40% market share. 
- **Pipeline Momentum**: First patient dosed with CD19 CAR-T therapy for progressive MS. 
- **Financial Strength**: $28.2M net income, $279M cash, and 70%+ gross-to-net margin. 
- **Strategic Differentiation**: 1/3 market share in IV anti-CD20, 5-year safety data, and simplified infusion schedule.

**【CEO Summary Section】**
- Q2 2025 marked strong performance for BRIUMVI, with nearly 1/3 of new IV anti-CD20 patients prescribed the therapy. 
- Subcu BRIUMVI development is on track for a 2028 launch, targeting the 35-40% self-administered anti-CD20 market segment. 
- A Phase III trial for subcu dosing (every other month vs. quarterly) and a study to consolidate infusions into a single dose are underway. 
- First patient dosed with azer-cel, a CD19 CAR-T therapy for progressive MS, advancing pipeline diversification.

**【CCO Commercial Update】**
- Q2 U.S. net sales: $139M (91% YoY growth), driven by record new patient enrollments and 70%+ persistence rates. 
- TV campaign boosted brand awareness, with 10%+ increase in patient-requested prescriptions. 
- Full-year guidance raised to $575M, reflecting Q3-Q4 seasonal growth acceleration. 
- BRIUMVI's twice-annual, 1-hour infusion and 5-year safety profile maintain competitive advantage.

**【CFO Financial Commentary】**
- Total revenue: $141.1M (91% YoY growth), with $138.8M from BRIUMVI. 
- OpEx: $71M (up 51% YoY due to R&D and commercial investments). 
- GAAP net income: $28.2M ($0.17 EPS), up 313% YoY. 
- Cash balance: $279M, supporting long-term strategy execution.

**【Q&A Highlights】**
- **Market Dynamics**: 40% of new anti-CD20 starts prefer subcu, while BRIUMVI captures 33% of IV segment. 
- **Device Details**: Subcu BRIUMVI will use a standard auto-injector, with bridging studies planned. 
- **Payer Trends**: No current subcu preference, but potential for accelerated shift in 1-2 years. 
- **Adherence**: 70%+ persistence at week 48, matching or exceeding competitor benchmarks.

TG Therapeutics, Inc. (TGTX) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: Q1 2025 US net sales of $119.7M (+137% YoY), with full-year guidance raised to $560M
- **Market Leadership**: 25%+ IV anti-CD20 market share, repeat prescriptions surpassing new starts
- **Innovation Pipeline**: 
  - Simplified 600mg single-dose regimen for new patients
  - 30-minute maintenance infusions in Phase 1
  - Subcu BRIUMVI pivotal trials on track for 2025
- **Financial Strength**: $276M cash balance, no material tariff impact anticipated
- **Growth Catalysts**: Direct-to-patient TV campaign, subcu formulation development, new indication exploration

**【CEO Opening Remarks】**
- Q1 2025 US net sales of BRIUMVI reached $119.7 million, up 137% YoY and 16% QoQ, driven by new patient enrollment and repeat prescriptions.
- BRIUMVI adoption is accelerating due to its unique 1-hour, twice-a-year infusion profile and growing real-world evidence of superior tolerability compared to competitors.
- Key milestones include: 
  - Launch of a simplified 600mg single-dose regimen for new patients (eliminating day 15 dose)
  - Phase 1 data showing safety of 30-minute maintenance infusions
  - Subcu BRIUMVI Phase 1 safety study progressing on track for pivotal trials in 2025
- Long-term goal: Become the #1 prescribed anti-CD20 therapy by dynamic market share

**【CCO Commercial Update】**
- Q1 2025 highlights:
  - 137% YoY growth in US net sales ($119.7M vs $50.5M)
  - 16% QoQ growth ($119.7M vs $103.2M)
  - March was highest month ever for repeat prescribers (60% of enrollments from hospitals)
  - Repeat prescriptions now exceed new prescriptions
- Growth drivers:
  - 25%+ market share in IV anti-CD20 segment
  - 16% sequential quarter-over-quarter growth in new patient starts
  - Strong persistence rates at 24/48 weeks
- 2025 initiatives:
  - Launch direct-to-patient TV campaign
  - Expand subcu BRIUMVI development (potential for quarterly dosing)
  - Evaluate new indications (e.g., Myasthenia Gravis)
- Updated full-year guidance: $560M US net revenue (vs prior $525M)

**【CFO Financial Review】**
- Q1 2025 financials:
  - US net product revenue: $119.7M (137% YoY growth)
  - GAAP net income: $5M ($0.03 EPS)
  - Operating expenses: $82M (tracking to $300M annual guidance)
  - Cash balance: $276M
- Key points:
  - Pre-launch inventory reserves fully depleted
  - Subcu BRIUMVI manufacturing costs (~$20M Q1) expected to fluctuate
  - No material impact anticipated from proposed tariffs

**【Q&A Highlights】**
1. **Competitive Dynamics**:
   - BRIUMVI gaining ~25% IV anti-CD20 market share
   - No impact from Zunovo launch
   - Switching trends stable (~consistent % of new starts from Ocrevus)
2. **Subcu Development**:
   - Pivotal trials for subcu BRIUMVI expected to start in 2025
   - Evaluating quarterly dosing regimen
   - Potential for new indications (e.g., Myasthenia Gravis)
3. **Manufacturing**:
   - North Carolina facility 3+ years from commercial readiness
   - Current South Korea manufacturing costs shielded from tariffs
4. **Profitability**:
   - Focused on revenue growth rather than near-term profitability
   - OpEx guidance maintained at $300M


TG Therapeutics (TGTX)-5 May 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: U.S. BRIUMVI sales hit $310 million in 2024, up 250% YoY, with Q4 at $103.6 million (24% QoQ growth).
- **Clinical Milestones**: 5-year data shows 92% no disability progression; subcutaneous BRIUMVI pivotal trial set for mid-2025.
- **Pipeline Expansion**: CAR-T therapy azer-cel Phase I study for progressive MS launching soon; MG expansion showing promise.
- **Financial Strength**: $311 million cash balance, 70-75% gross to net ratio, and 2042 patent protection for BRIUMVI.

**【CEO Summary Section】**
- Full year 2024 U.S. revenue reached $310 million, exceeding guidance and reflecting strong demand for BRIUMVI in RMS.
- Presented 5-year follow-up data showing 92% of patients free from disability progression and annualized relapse rate of 0.02.
- Launched ENHANCE trial with 30-minute maintenance infusion and 600mg single-dose regimen, aiming to simplify administration.
- Subcutaneous BRIUMVI bioavailability studies support potential for every-other-month dosing, with pivotal trial expected mid-2025.
- Expanded pipeline with azer-cel CAR-T therapy for progressive MS, receiving IND clearance for Phase I study.
- Secured 3 new patents extending BRIUMVI composition of matter protection to 2042.

**【CFO Financial Commentary】**
- Q4 2024 U.S. net product revenue: $103.6 million (24% QoQ growth, 16% YoY growth).
- Full year 2024 total global revenue: $329 million ($310M U.S. BRIUMVI + $12.5M ex-U.S. milestone).
- GAAP net income: $23 million (Q4) and $23 million (FY24), driven by strong BRIUMVI margins.
- Operating expenses: $206 million (FY24), below guided $250 million range.
- Cash position: $311 million as of Q4, supporting 2025 expansion plans.

**【Q&A Highlights】**
- **Subcutaneous BRIUMVI**: Pivotal trial expected mid-2025, targeting 12-month enrollment period. Design may include 200-250 patients per arm, with potential for every-other-month dosing.
- **Gross to Net Ratio**: Projected 70-75% for 2025, stable with U.S. payer coverage.
- **Market Share**: 25% of new IV CD20 starts in Q1 2025, up from 15% in 2024H2, driven by academic neurologist adoption.
- **CAR-T Pipeline**: Azer-cel Phase I study for progressive MS nearing first patient enrollment, focusing on dose-finding and B-cell depletion biomarkers.
- **Myasthenia Gravis**: Early exploratory data positive, with potential for cost-effective anti-CD20 therapy in underserved population.

Actual								-0.48	-0.47	-0.73	-0.69	-0.59	-0.65	-0.7	-0.51	-0.3	-0.39	-0.28	-0.34	0.73	-0.09	-0.07	0.04	0.02	0.15	0.03	0.17	2.43	0.14
Forecast								-0.358	-0.338	-0.4133	-0.5563	-0.52	-0.57	-0.635	-0.6123	-0.48	-0.2711	-0.3625	-0.2515	0.0572	-0.1003	-0.06	-0.0456	0.03	0.1572	0.1717	0.2112	0.2189	0.3525
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-34.08%	-39.05%	-76.63%	-24.03%	-13.46%	-14.04%	-10.24%	+16.71%	+37.50%	-43.86%	+22.76%	-35.19%	+1176.22%	+10.27%	-16.67%	+187.72%	-33.33%	-4.58%	-82.53%	-19.51%	+1010.10%	-60.28%

TGTX

TGTX fundamentals

TGTX Q4 2025 Earnings

Earnings Call

You can ask Aime

TGTX

TGTX fundamentals

TGTX Q4 2025 Earnings

Earnings Call

TGTX Earnings Call Summary for Q4/20258:30 AM on Feb 26, 2026

TGTX Earnings Call Summary for Q3/20258:30 AM on Nov 3, 2025

TGTX Earnings Call Summary for Q2/20258:30 AM on Aug 4, 2025

TGTX Earnings Call Summary for Q1/20258:30 AM on May 5, 2025

TGTX Earnings Call Summary for Q4/20248:30 AM on Mar 3, 2025

You can ask Aime